Canadian branded and generic pharma collaborate on drug shortages

In Canada, the Research-Based Pharmaceutical Companies (Rx&D) and the Canadian Generic Pharmaceutical Association (CGPA) this week announced their commitment and financial support in responding urgently to prescription drug shortages.

Jim Keon, president of CGPA, said: “Our members understand the anxiety and frustration that drug shortages cause Canadian patients, their families and health care professionals. We are pleased to work with our industry partners on this initiative to provide timely information to Canadian patients and health-care providers.”

For his part, Russell Williams, president of Rx&D, commented: “I am proud that the entire Canadian pharmaceutical industry is stepping up. This partnership will help ensure that Canadians and their healthcare professionals have access to the latest data on product availability, in real-time, online at all times. Our commitment is to provide accurate and timely information on all aspects of the pharmaceutical supply chain.”